Literature DB >> 2635737

The effect of aging on percutaneous absorption in man.

K V Roskos1, H I Maibach, R H Guy.   

Abstract

Despite much research into the mechanisms of cutaneous aging and the identification of significant age-associated biological and biophysical changes within the skin, the question "How does aging affect percutaneous absorption (PA) in vivo?" remains unanswered. We have made in vivo measurements of PA in young (18-40 years) and old (greater than 65 years) subjects. Standard radiotracer methodology was employed and PA was quantified from the urinary excretion profiles of 14C radiolabel (corrected for incomplete renal elimination). Testosterone (TST), estradiol (EST), hydrocortisone (HC), benzoic acid (BA), acetylsalicylic acid (ASA), and caffeine (CAFF) have been studied. Permeation of HC, BA, ASA, and CAFF was significantly (p less than 0.01, 0.01, 0.01, and 0.05, respectively) lower in aged subjects, whereas the absorption of TST and EST was similar in the two groups. Thus it appears that aging can affect PA in vivo and that relatively hydrophilic compounds are particularly sensitive. The diminished surface lipid content of "old" skin implies a diminished dissolution medium for compounds administered topically. It is reasonable to speculate that this physiologic change will impact most severely upon those permeants whose lipid solubility is lowest (that is, HC, BA, ASA, CAFF). Furthermore, the typically reduced hydration of aged stratum corneum will compound this effect for these chemicals. Conversely, highly lipid-soluble chemicals (TST and EST) may still be able to dissolve readily into the stratum corneum even when the available lipid medium is reduced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2635737     DOI: 10.1007/bf01062121

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  15 in total

1.  Mass balance and dose accountability in percutaneous absorption studies: development of a nonocclusive application system.

Authors:  D A Bucks; H I Maibach; R H Guy
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

2.  Effects of aging on fatty acids in skin surface lipids.

Authors:  M Nazzaro-Porro; S Passi; L Boniforti; F Belsito
Journal:  J Invest Dermatol       Date:  1979-07       Impact factor: 8.551

3.  Na22Cl skin clearance in humans and its relation to skin age.

Authors:  S J DeSalva; G Thompson
Journal:  J Invest Dermatol       Date:  1965-11       Impact factor: 8.551

Review 4.  Morphology of aged skin.

Authors:  R M Lavker; P S Zheng; G Dong
Journal:  Dermatol Clin       Date:  1986-07       Impact factor: 3.478

5.  General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment.

Authors:  E Nakashima; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

6.  Effect of ageing on the blistering of human skin with ammonium hydroxide.

Authors:  G L Grove; S Duncan; A M Kligman
Journal:  Br J Dermatol       Date:  1982-10       Impact factor: 9.302

7.  Percutaneous absorption of malathion in the guinea-pig: effect of repeated topical application.

Authors:  D A Bucks; J P Marty; H I Maibach
Journal:  Food Chem Toxicol       Date:  1985-10       Impact factor: 6.023

8.  Age-related changes in sebaceous gland activity.

Authors:  P E Pochi; J S Strauss; D T Downing
Journal:  J Invest Dermatol       Date:  1979-07       Impact factor: 8.551

9.  Effect of aging on sebaceous gland activity and on the fatty acid composition of wax esters.

Authors:  A Yamamoto; S Serizawa; M Ito; Y Sato
Journal:  J Invest Dermatol       Date:  1987-11       Impact factor: 8.551

10.  In vitro percutaneous penetration: evaluation of the utility of hairless mouse skin.

Authors:  R S Hinz; C D Hodson; C R Lorence; R H Guy
Journal:  J Invest Dermatol       Date:  1989-07       Impact factor: 8.551

View more
  18 in total

1.  The utility of naphthyl-keratin adducts as biomarkers for jet-fuel exposure.

Authors:  Juei-Chuan C Kang-Sickel; Mary Ann Butler; Lynn Frame; Berrin Serdar; Yi-Chun E Chao; Peter Egeghy; Stephen M Rappaport; Christine A Toennis; Wang Li; Tatyana Borisova; John E French; Leena A Nylander-French
Journal:  Biomarkers       Date:  2011-09-30       Impact factor: 2.658

Review 2.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  [Contact dermatitis. II].

Authors:  P J Frosch; T Rustemeyer; A Schnuch
Journal:  Hautarzt       Date:  1996-12       Impact factor: 0.751

Review 4.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 6.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

7.  (31)P solid-state NMR based monitoring of permeation of cell penetrating peptides into skin.

Authors:  Pinaki R Desai; Ashley R Cormier; Punit P Shah; Ram R Patlolla; Anant K Paravastu; Mandip Singh
Journal:  Eur J Pharm Biopharm       Date:  2013-05-20       Impact factor: 5.571

Review 8.  Use of transdermal drug formulations in the elderly.

Authors:  Laure-Zoé Kaestli; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry; Nicole Vogt-Ferrier
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Percutaneous absorption and age. Implications for therapy.

Authors:  K V Roskos; H I Maibach
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

10.  Analysis of the expression pattern of involucrin in human scalp skin and hair follicles: hair cycle-associated alterations.

Authors:  Mohamed A Adly; Hanan A Assaf
Journal:  Histochem Cell Biol       Date:  2012-07-14       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.